Molecular Identification of Extended-Spectrum β-lactamase and Integron Genes in Klebsiella pneumoniae

Ehsan Estabraghi,1 Taghi Zahraei Salehi,2 Kumarss Amini,3 Mahmoud Jamshidian4

1Department of Microbiology, Science and Research Branch, Islamic Azad University, Tehran, Iran, 2Department of Microbiology and Immunology, Faculty of Veterinary Medicine, University of Tehran, Tehran, Iran, 3Department of Microbiology, School of Basic Sciences, Saveh Branch, Islamic Azad University, Saveh, Iran, 4Department of Microbiology, Science and Research Branch, Islamic Azad University, Tehran, Iran.

ABSTRACT

Introduction: Infections caused by Gram negative bacteria, producing extended-spectrum β-lactamase, including Klebsiella pneumoniae are increasing all over the world with high morbidity and mortality. The aim of the present study was determined antimicrobial profile susceptibility and the prevalence of antibiotic resistance genes by multiplex PCR.

Methods: In the present study, we obtained one-hundred isolates of K. pneumoniae from different clinical samples. The antibiotic susceptibility testing was done in thirteen antibiotic and, therefore, M-PCRs were conducted using the DNA amplification for detection of ESBLs (blaTEM, blaCTX-M, blaSHV) and int (I, II, III) genes.

Results: The results of resistance to amoxicillin/clavulanate, ciprofloxacin, amikacin, trimethoprim-sulfamethoxazole, cefotaxime, ampicillin, aztreonam, imipenem, gentamicin, ceftazidime, Cefepime, ceftriaxone and levofloxacin were obtained 37%, 37%, 93%, 84%, 52%, 87%, 59%, 8%, 24%, 67%, 52%, 43% and 26%, respectively. The frequency of the extended-spectrum β-lactamase K. pneumoniae was obtained 37%. The prevalence of resistance genes of ESBLs in the M-PCR method showed that the blaTEM, blaCTX and blaSHV were 38%, 24% and 19%, respectively, however, only 8 (8%) out of 100 isolates were found to have positive outcomes for the existence of class 1 integrons and there were no detected class 2 or class 3 integrons.

Conclusions: Our results recommend the likely co-carriage of some ESBLs genes and antibiotic resistance integrons on the same plasmids harboring the MDR genes.

Keywords: Klebsiella pneumonia; integrons; drug resistance.

INTRODUCTION

Klebsiella pneumoniae (K. pneumoniae) is one of the most important causative agents both in form of community-acquired and hospital acquired infections such as urinary tract infections, pneumonia, septicemia and meningitis.1 Multidrug resistance has been developing trouble clinically, particularly for elderly and immunocompromised patients, and moreover infant with immature body physiology have the least

Correspondence: Taghi Zahraei Salehi, Department of Microbiology, Faculty of Veterinary Medicine, University of Tehran, P.O. Box: 14155-6453, Tehran, Iran. Email: tsalehi@ut.ac.ir, Phone: +98-21-66427517.
capability against infection from MDR pathogens. The release of extended-spectrum β-lactamases (ESBLs) are unique of the significant mechanisms of antimicrobial agents resistance. The appearance of ESBLs in Enterobacteriaceae groups has been a problem of medical concern. ESBLs producing K. pneumonia can degrade a wide-rangiing of beta-lactam groups such as penicillins, cephalosporins, carbapenems and cephemycins. In general, ESBLs are distributed into four classes A, B, C and D. TEM benzylpenicillinase (TEM) and sulfhydryl variable (SHV) are present in class A ESBLs. Some researchers have described various occurrences of ESBLs between 6% and 88% in difference health care locations particularly between K. pneumoniae and E. coli. SHV type β-lactamases relate to high level resistance to ceftazidime, but not to Cefazolin and cefotaxime, while CTX-M β-lactamases are more an effective against cefotaxime. In contrast, TEM β-lactamases confer resistance to oxyimino-β-lactams groups, such as ceftazidime, cefotaxime, and aztreonam. In addition to ESBLs, the transportable genetic elements, such as integrons, provide for the evolution and distribution of MDR genes (blaTEM, blaCTX-M, blaSHV, and int genes (I,II,III)) in K. pneumoniae by vertical or horizontal transmission. According to the variation aminoacid sequence of the Int protein, 5 classes of integrons have been identified. Three classes of antibiotic resistance integrons (ARIs) (classes 1, 2, and 3) have been generally complexed in MDR phenotypes criteria and are recognized depending on their particular integrase genes. The transportable class 1 integrons are related to transposon Tn21 and have been commonly occur in ESBL producing clinical isolates of K. pneumoniae. However, Class 2 integrons found less frequently in ESBL-producing bacteria like K. pneumoniae and Escherichia coli, and class 3 integrons are infrequently in ESBL-producing K. pneumoniae. In previous reports have confirmed the relations among ESBL producing bacteria and resistance to several groups of antibiotics, as well blaESBL with ARI gene carriage in clinical isolates of K. pneumoniae. Unfortunately, in the last decades, the incidence of ESBL-producing K. pneumoniae and their resistance is raising. The identification of ESBLs genes, involving CTX-M ,TEM and SHV, by molecular methods in bacteria that producing ESBL and their antimicrobial susceptibility profile can provide appropriate evidence about their high risk factors and epidemiology related to their infections. A few studies have been conducted to identify the types of ESBLs producing Enterobacteriaceae in Iranian hospitals. The aim of the present study was detection of blaTEM, blaCTX-M, blaSHV and int genes (I,II,III) in the clinical K. pneumonia strains isolated from two large urban teaching general hospitals in Tehran, Iran by multiplex PCR (M-PCR) and their antibiotic resistance profile.

METHODS

This cross-sectional study was directed during a one year period of time from April 2014 till March, 2015, in two teaching hospitals in Tehran, Iran. Generally, 100 non-repetitive K. pneumoniae strains were obtained from different clinical specimen including blood, skin lesions, broncho-alveolar lavage (BAL), urine, sputum, cerebrospinal fluid (CSF), Pus/swap, pleural effusion, ascites and catheter. Each sample was cultured on the Mac Conkey agar (Merck Co., Germany) and incubated in 37 °C for 24 h. Then, all suspected grown colonies were recognized as K. pneumoniae by standard biochemical and microbiological tests such as, urease, Gram staining, oxidase, motility, citrate utilization, urease production, TSI, KIA, MR-VP, SIM and confirmed API 20E system. (Analytab, Inc., New York).

Antibiotic susceptibility test was achieved by disc diffusion method on the Mueller- Hinton Agar (Merck Co., Germany) plates agreeing with Clinical and Laboratory Standards Institute (CLSI) guideline for the following antibiotics: amoxicillin/clavulanate (Aug; 20/10 μg), ciprofloxacine (CIP: 5 μg), amikacin (AK: 30 μg), thimetprim-sulfamethoxazole (TS, 2.5 μg), cefotaxime (CTX: 30 μg), Ampicillin (AMP: 10 μg), Aztreonam (AZT: 30 μg), imipenem (IPM: 10 μg), gentamycin (GEN: 10 μg), cefazidime (CAZ: 30 μg), cefepime (FEP: 30 μg), ceftazidime(CRO: 30 μg), imipenem (IMP: 10μg) and levofloxacine (LEV: 5μg) ( Mast, Merseyside, UK). Briefly, a bacterial suspension was achieved from fresh cultures. The turbidity of each bacterial suspension was adjusted equivalent to a no. 0.5 McFarland standard and then injected on Mueller-Hinton agar (Oxoid, UK). Diameter of inhibition zones was dignified after incubation at 37°C for 18-24 hours, and results were reported as susceptible, intermediate, and resistant. The standard strain of K. pneumoniae ATCC 1029 was used as a quality control.

M-PCRs were performed using the DNA amplification instrument master cycler gradient (Eppendorf Co., Germany) for detection of ESBLs genes (blaTEM, blaCTX-M and blaSHV) and int genes (I,II,III). Genomic DNA was acquired from K. pneumoniae colonies grown overnight on blood agar (Merck Co., Germany) plates by the boiling lysis method. Briefly, a loopful of bacterial colonies was suspended in the 700 μl sterile distilled water and boiled for 10 min and centrifuged at 7000 x g for 4 min at 4°C and then cooling in ice for 10 minutes and centrifugation for 3 min at 8000 x g. The concentration and the quality of the extracted cellular DNA were assessed using a Nanodrop spectrophotometer (ND-1000; Thermo Scientific; Wilmington, DE, USA). The genes encoding carbapenemases were amplified using
the primer sequences, which were presented in Table 1, for m-PCR. M-PCR was done for amplification of ESBLs genes (blaTEM, blaCTX-M, blaSHV) and in a volume of 1.5 μl of extracted genomic DNA was added to a total volume of 25 μl PCR reaction mixture including 2.5 μl of 10 × PCR buffer, 1.5 μl MgCl₂ (50 mM), 0.5 μl dNTPs (10 mM), 1.25 μl of each primer, 0.5 μl of Taq DNA polymerase (5 U/μl) (Amplicon Co., Denmark) and 8.5 μl sterile distilled water. The reaction mixture was performed with the following PCR procedure: Denaturation at 94°C for 1 min, 35 cycles with denaturation at 94°C for 30 s, annealing at 59°C for 30 s, extension at 72°C for 1 min and final extension at 72°C for 6 min. So, amplification of int genes (I, II, III), the reaction mixture was completed in a thermal gradient cycler (Eppendorf Co., Germany) with the following PCR protocol: The cycling conditions were one cycle of 5 min at 95 °C; 30 cycles of 1 min at 95°C, 1 min at 65°C, and 1 min at 72°C; and one cycle of 10 min at 72°C (11).

RESULTS

The mean age of the population studied was 47 ± 1.5 years, with a range of 14 to 76 years. The isolates were collected from patients belonging to various age groups: 10-25 years No; 23, 26-40 No; 28, 41-55 years No; 36, 56-60 years No; 8 and 60-76 years No; 5. Sixty seven (67%) patients were male and 33 (33%) patients were female.

Out of 374 different clinical samples, 100 (26.7%) K. pneumoniae isolates were obtained. The specimens included the blood (n = 7, 7%), skin lesions (n = 9, 9%), BAL (n = 5, 5%), urine (n = 62, 62%), sputum (n = 6, 6%), CSF (n = 3, 3%), Pleural effusion (n = 2, 2%), ascites (n = 2, 2%), and catheter (n = 3, 3%). The distribution analysis of K. pneumoniae strains showed that the most isolates (62%) were obtained from the urine and the lowest (1%) found to be isolated from pleural effusion.

The antibiotic susceptibility testing by antibiogram method showed that the percentage of resistance to amoxicillin/clavulanate, ciprofloxacin, amikacin, trimethoprim-sulfamethoxazole, cefotaxime, ampicillin, aztreonam, imipenem, gentamicin, ceftazidime, cefepime, ceftriaxone and levofloxacin were 37%, 37%, 93%, 84%, 52%, 87%, 59%, 8%, 24%, 67%, 52%, 43% and 26%, respectively (Table 2).

ESBLs genes amplification test showed that the prevalence of blaTEM, blaCTX-M and blaSHV were 38%, 24% and 19%, respectively. M-PCR simultaneously amplified and identified the existence of blaTEM (445 bp), blaCTX-M (593 bp) and blaSHV (747 bp), respectively (Figure 1). Molecular distribution analysis of integrons genes showed that, only 8 (8%) out of 100 isolates were found to have positive outcomes for the existence of class 1 integrons and no class 2 or class 3 integrons were identified between isolates (Figure 2).

Table 1. The nucleotide sequences of the primers used for the M-PCR.

| Genes   | Oligonucleotide sequence (5ʹ→3ʹ) | Size of amplicon (bp) |
|---------|----------------------------------|-----------------------|
| bla-SHV | F = 5ʹ-ATGCCTATATTCGCTTGTG-3ʹ   | 747                   |
|         | R = 5ʹ-TGCTTTGTTATTCGGGCAG-3ʹ   |                       |
| TEM-1   | F = 5ʹ-TGCCCCATACACTTTCTCAATTGA-3ʹ | 445                  |
|         | R = 5ʹ-ACGCTCACGGCTCCAGATTAT-3ʹ |                       |
| CTX-M   | F = 5ʹ-ATGTCAGGACACGTAAGTGATG-3ʹ | 593                  |
|         | R = 5ʹ-TGGGTAAGTACGAGGATGCG-3ʹ   |                       |
| intI    | F = 5ʹ-GCTTTGTGTTTTCTACGG-3ʹ    | 558                  |
|         | R = 5ʹ-GATGCTTGTTTTCTACGG-3ʹ    |                       |
| intII   | F = 5ʹ-CACCGATATGCGACAASAGGT-3ʹ | 789                  |
|         | R = 5ʹ-GTAGACACAGTGAGCAAAAT-3ʹ  |                       |
| intIII  | F = 5ʹ-GCCTCCCGGCAACGACATTCAG-3ʹ | 979                  |
|         | R = 5ʹ-AACGGATCTGCCAACCTGACT-3ʹ |                       |
Figure 1. M-PCR amplification of ESBLs genes in 12 selected isolates of K. pneumoniae. lane +: Quality control (K. pneumoniae ATCC 1029), lane : negative control; E. coli ATCC 25922, Lane 25-36: MPCR product of these genes; M: 100 bp DNA size marker.

Figure 2. M-PCR amplification of int genes in 4 selected isolates of K. pneumoniae. lane +: Quality control (K. pneumoniae ATCC 1029), lane : negative control; E. coli ATCC 25922, Lane 1-4: MPCR product of these genes; M: 100 bp DNA size marker.

Table 2. Antibiotics resistance pattern in K. pneumoniae isolates.

| Antibiotic                  | R (%) | I (%) | S (%) |
|-----------------------------|-------|-------|-------|
| amoxicillin/clavulanate (Aug) | 37 (37) | 0 (0) | 63 (63) |
| ciprofloxacin (CIP)          | 37 (37) | 5 (5) | 58 (58) |
| amikacin (AK)                | 93 (93) | 3 (3) | 4 (4)  |
| trimethoprim-sulfamethoxazole (TS) | 84 (84) | 4 (4) | 12 (12) |
| cefotaxime (CTX)             | 52 (52) | 1 (1) | 47 (47) |
| ampicillin (AMP)             | 87 (87) | 2 (2) | 11 (11) |
| aztreonam (AZT)              | 59 (59) | 1 (1) | 40 (40) |
| imipenem (IPM)               | 8 (8)  | 9 (9) | 83 (83) |
| gentamicin (GEN)             | 24 (24) | 6 (6) | 70 (70) |
| ceftazidime (CAZ)            | 67 (67) | 2 (2) | 31 (31) |
| cefepime (FEP)               | 52 (52) | 0 (0) | 48 (48) |
| ceftriaxone (CRO)            | 43 (43) | 1 (1) | 56 (56) |
| levofloxacin (LEV)           | 26 (26) | 0 (0) | 74 (74) |

*I= Intermediate, *R= Resistance, *S= Susceptible.

Table 3. Antibiotic resistance rates among Non-ESBL producing K. pneumoniae strains and ESBL-producing K. pneumoniae strains.

| Antibiotic                  | ESBL producing K. pneumoniae strains (%) | Non-ESBL producing K. pneumoniae strains (%) |
|-----------------------------|----------------------------------------|--------------------------------------------|
| amoxicillin/clavulanate (Aug) | 37                                     | 63                                         |
| ciprofloxacin (CIP)          | 21                                     | 42                                         |
| amikacin (AK)                | 18                                     | 45                                         |
| trimethoprim-sulfamethoxazole (TS) | 32         | 31                                         |
| cefotaxime (CTX)             | 14                                     | 49                                         |
| ampicillin (AMP)             | 35                                     | 28                                         |
| aztreonam (AZT)              | 12                                     | 51                                         |
| imipenem (IPM)               | 6                                      | 57                                         |
| gentamicin (GEN)             | 31                                     | 32                                         |
| ceftazidime (CAZ)            | 33                                     | 30                                         |
| cefepime (FEP)               | 24                                     | 39                                         |
| ceftriaxone (CRO)            | 15                                     | 48                                         |
| levofloxacin (LEV)           | 7                                      | 56                                         |

DISCUSSION

At first, ESBLs-producing K. pneumoniae was discovered in 1983.17 Infections caused by K. pneumoniae that ESBL-producing are raising in several countries such as Iran,18 India19,20 and Italy.21 Resistance to various antibiotic is related to extent of transmissible plasmids
and integrons which can be integrated on the plasmids or chromosome. In order to, we evaluated antibiotic susceptibility of 100 strain of K. pneumoniae to thirteen antibiotic. The high resistance rate were related to AK (93%), TS (84%), AMP (87%), AZT (59%), GEN (67%) and FEP (52%). Amiri et al, (2016) reported resistance to ampicillin, cefazidime, ceftriaxone, aztreonam and cefotaxime was (92%), (67%), (65%), (64%) and (59%), respectively, which is approximately similar to our results. Our results indicated only eight ESBL-producing isolates were shown to be resistance to imipenem in disk diffusion method. This result of high susceptibility (83%) to imipenem was agreement to Mansury et al, (2016), Ahmad et al, (2009), Amiri et al, (2016) and Edelstein et al, (2003) studies According to disk diffusion results, only three isolates of K. pneumoniae were resistant to all antibiotics. In present study, MDR isolates are resistant to three classes of antimicrobial agents, therefore, 31% MDR isolates were obtained. This finding is mismatch with Mansury et al (2016) study. A total of 52% and 67% isolates were resistant to the third generation cephalosporins (ceftazidime and cefotaxime), this outcomes is compatible with Ullah et al, (2009), Amiri et al, (2016) and Jalalpoor et al, (2011) studies. Of these MDR-isolates, 28 strains were positive ESBL production (28%). The present results were correlated with the Shukla et al., (2004) and Sarojamma et al, (2011) reported that 28% and 32% ESBL production, respectively. Nowadays, a critical increase in ESBL-producing Klebsiella spp. was also reported from 4.2–44% (USA), 28.4% (Spain), 78.6% (Turkey) (38), 20% (Algeria), and 51% (China). Our results indicated the high incidence of positive ESBL production was showed in urine (14%) samples. This research was conducted to identify the existence of blaTEM, blaSHV, blaCTX-M, and integrons genes (I, II, III) in ESBL producing K. pneumoniae. The M-PCR results was for each resistance genes as follows: the blaTEM gene only, detected in 38% (14/37); the blaCTX gene in 24% (9/37) and the blaSHV gene in 19% (7/37); blaTEM and blaSHV detected in 8% (3/37); blaTEM and blaCTX-M detected in 16% (6/37). Bora et al., (2014) reported between three ESBLs profile genotypes, the most predominant genotype was observe to be blaTEM in K. pneumoniae (77.58%) ESBL producing strains. Monstein et al, (2007) reported the blaSHV distinguished in 8% (3/37), blaSHV and blaTEM discovered in 2.7% (1/37), and blaTEM, blaSHV, and blaCTX-M discovered in 8% (3/37) strains of K. pneumoniae. Hassan and Abdalhamid (2014) indicated increase in the blaCTX-M (97.4%) in compared with to prevalence of blaSHV (23.1%) in K. pneumoniae. In contrast, in European countries, East Asia and Latin America, in current study the blaTEM variations have displaced blaCTX-M and blaSHV enzymes as the major beta-lactamases produced by isolates of K. pneumoniae. This outcome reflects significant raise in the blaTEM genotype in Iran. In Arab countries, the principal ESBL was blaCTX-M. In addition ESBLs genes, integrons genes was evaluated in 100 isolates of K. pneumoniae. Our results was indicated eight isolates were positive outcomes for the existence of class 1 integrons and no class 2 or class 3 integrons were identified between isolates. This finding is comparable with lima et al, and Ashayeri et al., studies. Since, only a rare studies about class 3 integron has been described and categorized. Mobarak-Qamsari et al, described 22 (44%) integron class 1, only 3 (6%) isolates of K. pneumoniae carried integron class 2 and none of them contained of integon class 3. Possible critical role of integrons genes in distribution of ESBL-encoding blaTEM gene among ESBL-producing K. pneumoniae clinical isolates may be inferred. This highlights the increasing complication of antimicrobial agent resistance problems, and the explanations for this condition need further investigation.

CONCLUSIONS

In conclusion, this project approves that a high level of blaTEM and class 1 integrons-positive ESBL K. pneumoniae is circulating in two hospitals of Tehran, Iran. The trend of MDR profiles related with the recovery of the blaTEM and lass 1 integron genes is worrying. This highlights values is require for establish an antibiotic susceptibility surveillance network for monitoring of Enterobacteriaceae spp., infection in Iran.

ACKNOWLEDGMENT

This study was financially supported by the Islamic Azad University, Science and Research Branch (SRBIAU). We thank the following hospitals for referring isolates and epidemiological and demographic data for use in this study: Rasool Akram, Ali Asghar Children’s Hospital.

REFERENCES

1. Tsay R-W, Siu L, Fung C-P, Chang F-Y. Characteristics of bacteremia between community-acquired and nosocomial Klebsiella pneumoniae infection: risk factor for mortality and the impact of capsular serotypes as a herald for community-acquired infection. Archives of internal medicine. 2002;162(9):1021-7.

2. Hirsch EB, Tam VH. Detection and treatment options for Klebsiella pneumoniae carbapenemases (KPCs): an emerging cause of multidrug-resistant infection. Journal of antimicrobial chemotherapy. 2010.dkq108.
3. Paterson DL, Hujer KM, Hujer AM, Yeiser B, Bonomo MD, Rice LB, et al. Extended-spectrum β-lactamases in Klebsiella pneumoniae bloodstream isolates from seven countries: dominance and widespread prevalence of SHV-and CTX-M-type β-lactamases. Antimicrobial Agents and Chemotherapy. 2003;47(11):3554-60.

4. Machado E, Coque TM, Cantón R, Novais À, Sousa JC, Baquero F, et al. High diversity of extended-spectrum β-lactamases among clinical isolates of Enterobacteriaceae from Portugal. Journal of antimicrobial chemotherapy. 2007;60(6):1370-4.

5. Branger C, Zamfir O, Geoffroy S, Laurans G, Arlet G, Thien HV, et al. Genetic background of Escherichia coli and extended-spectrum beta-lactamase type. Emerg Infect Dis. 2005;11(1):54-61.

6. SharMa M, PathaK S, SrivaStava P. Prevalence and antibiogram of Extended Spectrum β-Lactamase (ESBL) producing Gram negative bacilli and further molecular characterization of ESBL producing Escherichia coli and Klebsiella spp. J Clin Diagn Res. 2013;7(10):2173-7.

7. Bush K, Jacoby GA. Updated functional classification of β-lactamases. Antimicrobial Agents and Chemotherapy. 2010;54(3):969-76.

8. Laroche E, Pawlak B, Berthe T, Skurnik D, Petit F. Occurrence of antibiotic resistance and class 1, 2 and 3 integrons in Escherichia coli isolated from a densely populated estuary (Seine, France). FEMS microbiology ecology. 2009;68(1):118-30.

9. Poirel L, Le Thomas I, Naas T, Karim A, Nordmann P. Biochemical sequence analyses of GES-1, a novel class A extended-spectrum β-lactamase, and the class 1 integron In52 from Klebsiella pneumoniae. Antimicrobial Agents and Chemotherapy. 2000;44(3):622-32.

10. Correia M, Boavida F, Grosso F, Salgado M, Lito L, Cristina JM, et al. Molecular characterization of a new class 3 integron in Klebsiella pneumoniae. Antimicrobial Agents and Chemotherapy. 2003;47(9):2838-43.

11. Ashayeri-Panah M, Feizabadi MM, Eftekhar F. Correlation of Multi-drug Resistance, Integron and bla ESBL Gene Carriage With Genetic Fingerprints of Extended-Spectrum β-Lactamases Producing Klebsiella pneumoniae. Jundishapur Journal of Microbiology. 2014;7(2).

12. Endimiani A, Hujer AM, Hujer KM, Gatta JA, Schriver AC, Jacobs MR, et al. Evaluation of a commercial microarray system for detection of SHV-, TEM-, CTX-M-, and KPC-type β-lactamase genes in Gram-negative isolates. Journal of clinical microbiology. 2010;48(7):2618-22.

13. Tumbarello M, Spanu T, Sanguinetti M, Citton R, Montuori E, Leone F, et al. Bloodstream infections caused by extended-spectrum β-lactamase-producing Klebsiella pneumoniae: risk factors, molecular epidemiology, and clinical outcome. Antimicrobial Agents and Chemotherapy. 2006;50(2):498-504.

14. Odumosu BT, Adeniyi BA, Chandra R. Analysis of integrons and associated gene cassettes in clinical isolates of multidrug resistant Pseudomonas aeruginosa from Southwest Nigeria. Annals of clinical microbiology and antimicrobials. 2013;12(1):1.

15. Feizabadi MM, Delfani S, Raji N, Majnooni A, Aligholi M, Shahcheraghi F, et al. Distribution of bla TEM, bla SHV, bla CTX-M genes among clinical isolates of Klebsiella pneumoniae at Labbafinejad Hospital, Tehran, Iran. Microbial drug resistance. 2010;16(1):49-53.

16. Nasehi L, Shahcheraghi F, Nikbin VS, Nematzadeh S. PER, CTX-M, TEM and SHV Beta-lactamases in clinical isolates of Klebsiella pneumoniae isolated from Tehran, Iran. Iranian Journal of Basic Medical Sciences. 2010;13(3):111-8.

17. Knothe H, Shah PDP, Kermery V, Antal M, Mitsuhashi S. Transferable resistance to cefotaxime, cefoxitin, cefamandole and cefuroxime in clinical isolates of Klebsiella pneumoniae and Serratia marcescens. Infection. 1983;11(6):315-7.

18. Derakhshan S, Peerayeh SN, Fallah F, Bakhshishi R, Rahbar M, Ashrafi A. Detection of class 1, 2, and 3 integrons among Klebsiella pneumoniae isolated from children in Tehran hospitals. Archives of Pediatric Infectious Diseases. 2014;2(1):164-8.

19. Hansotia JB, Agarwal V, Pathak A, Saoji A. Extended spectrum beta-lactamase mediated resistance to third generation cephalosporins in Klebsiella pneumoniae in Nagpur, central India. The Indian journal of medical research. 1997;105:158-61.

20. Manchanda V, Singh N, Goyal R, Kumar A, Thukral S. Phenotypic characteristics of clinical isolates of Klebsiella pneumoniae & evaluation of available phenotypic techniques for detection of extended spectrum beta-lactamases. Indian Journal of Medical Research. 2005;122(4):330.

21. Perilli M, Dell’Amico E, Segatore B, de Massis MR, Bianchi C, Luzzaro F, et al. Molecular characterization of extended-spectrum β-lactamases produced by nosocomial isolates of Enterobacteriaceae from an Italian nationwide survey. Journal of clinical microbiology. 2002;40(2):611-4.

22. Ranjbar R, Giammanco GM, Farshad S, Owlia P, Aleo A, Mammina C. Serotypes, antibiotic resistance, and class 1 integrons in Salmonella isolates from pediatric cases of enteritis in Tehran, Iran. Foodborne pathogens and disease. 2011;8(4):547-53.

23. Amiri A, Firoozeh F, Moniri R, Zibaei M. Prevalence of CTX-M-Type and PER Extended-Spectrum β-Lactamases Among Klebsiella spp. Isolated From Clinical Specimens in the Teaching Hospital of Kashan, Iran. Iranian Red Crescent Medical Journal. 2016;18(3).

24. Mansury D, Motamedifar M, Sarvari J, Shirazi B, Khaledi A. Antibiotic susceptibility pattern and identification of extended spectrum β-lactamases (ESBLs) in clinical isolates of Klebsiella pneumoniae from Shiraz, Iran. Iranian journal of microbiology. 2016;8(1):55.

25. Ahmad S, Al-Juaif NF, Aleni FQ, Mattar EH, Bakheet OE-S. Prevalence, Antibiotic Susceptibility Pattern and Production of Extended-Spectrum β-Lactamases Amongst Clinical Isolates of Klebsiella pneumoniae at Armed Forces Hospital in Saudi Arabia. Journal of the College of Physicians and Surgeons Pakistan. 2009;19(4):264-5.

26. Edelstein M, Pimkin M, Palagin I, Edelstein I, Strachoulski L. Prevalence and molecular epidemiology of CTX-M extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae in Russian hospitals. Antimicrobial Agents and Chemotherapy.
27. Paterson DL. Resistance in gram-negative bacteria: Enterobacteriaceae. The American journal of medicine. 2006;119(6):S20-58.

28. Ullah F, Malik SA, Ahmed J. Antimicrobial susceptibility pattern and ESBL prevalence in Klebsiella pneumoniae from urinary tract infections in the North-West of Pakistan. African Journal of Microbiology Research. 2009;3(11):676-80.

29. Jalalpoor S. Antibiotic Resistant Pattern in ESBLs Producer Klebsiella Pneumoniae Strains Isolated of Hospitalized and Out Patients Acquired Urinary Tract Infection. Journal of Isfahan Medical School. 2011;29(142).

30. Shukla I, Tiwari R, Agrawal M. Prevalence of extended spectrum-lactamase producing Klebsiella pneumoniae in a tertiary care hospital. Indian journal of medical microbiology. 2004;22(2):87.

31. Sarojamma V, Ramakrishna V. Prevalence of ESBL-producing Klebsiella pneumoniae isolates in tertiary care hospital. ISRN microbiology. 2011;2011.

32. Saurina G, Quale JM, Manikal VM, Oydna E, Landman D. Antimicrobial resistance in Enterobacteriaceae in Brooklyn, NY: epidemiology and relation to antibiotic usage patterns. Journal of antimicrobial chemotherapy. 2000;45(6):895-8.

33. Mathai D, Lewis MT, Kugler KC, Pfaffer MA, Jones RN, Hospital CHM, et al. Antibacterial activity of 41 antimicrobials tested against over 2773 bacterial isolates from hospitalized patients with pneumonia: I—results from the SENTRY Antimicrobial Surveillance Program (North America, 1998). Diagnostic microbiology and infectious disease. 2001;39(2):105-16.

34. Winokur P, Canton R, Casellas J-M, Legakis N. Variations in the prevalence of strains expressing an extended-spectrum β-lactamase phenotype and characterization of isolates from Europe, the Americas, and the Western Pacific region. Clinical infectious diseases. 2001;32(Supplement 2):S94-S103.

35. Cordero L, Rau R, Taylor D, Ayers LW. Enteric gram-negative bacilli bloodstream infections: 17 years' experience in a neonatal intensive care unit. American journal of infection control. 2004;32(4):189-95.

36. Romero EDV, Padilla TP, Hernández AH, Grande RP, Vázquez MF, García IG, et al. Prevalence of clinical isolates of Escherichia coli and Klebsiella spp. producing multiple extended-spectrum β-lactamases. Diagnostic microbiology and infectious disease. 2007;59(4):433-7.

37. Kuo K, Shen Y, Hwang K. Clinical implications and risk factors of extended-spectrum beta-lactamase-producing Klebsiella pneumoniae infection in children: a case-control retrospective study in a medical center in southern Taiwan. Journal of Microbiology, Immunology and Infection. 2007;40(3):248-54.

38. Hosoglu S, Gundes S, Kolaylı F, Karadenizli A, Demirdag K, Gunaydın M, et al. Extended-spectrum beta-lactamases in ceftazidime-resistant Escherichia coli and Klebsiella pneumoniae isolates in Turkish hospitals. Indian journal of medical microbiology. 2007;25(4):346.